glp 1 agonist saxenda Teva brings first generic GLP-1 to US market with copycat approval GLP-1 Agonists - FAQ —
Description
The oral non-peptide GLP-1 receptor agonist market was dominated by North America in 2025 due to the high prevalence of obesity and diabetes, strong pharmaceutical research capabilities, and widespread adoption of innovative therapeutics
European Journal of Pharmacology, 878 ,
3 Some of these fake pens have contained insulin instead of semaglutide, causing people to be hospitalised with dangerously low blood sugar levels (hypoglycaemia)
Psychiatry Neurosci
John M, Kalra S, Nair T
doi: 10.1177/20420188231222367 11 MadsenMSAHolmJBPallejAWismannPFabriciusKRigboltKet al
